111 related articles for article (PubMed ID: 10465549)
1. Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.
Vara Prasad JV; Markoski LJ; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hagen SE; Tait BD; Lunney EA; Tummino PJ; Ferguson D; Holler T; Hupe D; Nouhan C; Gracheck SJ; VanderRoest S; Saunders J; Iyer K; Sinz M
Bioorg Med Chem Lett; 1999 Aug; 9(15):2217-22. PubMed ID: 10465549
[TBL] [Abstract][Full Text] [Related]
2. Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.
Prasad JV; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hamilton HW; Hagen SE; Markoski LJ; Steinbaugh BA; Tait BD; Humblet C; Lunney EA; Pavlovsky A; Rubin JR; Ferguson D; Graham N; Holler T; Hupe D; Nouhan C; Tummino PJ; Urumov A; Zeikus E; Zeikus G; Gracheck SJ; Erickson JW
Bioorg Med Chem; 1999 Dec; 7(12):2775-800. PubMed ID: 10658583
[TBL] [Abstract][Full Text] [Related]
3. Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing achiral 3-(4-amino/carboxamide-2-t-butyl,5-methylphenyl thio) moiety: antiviral activities and pharmacokinetic properties.
Vara Prasad JV; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hagen SE; Markoski LJ; Tait BD; Lunney EA; Tummino PJ; Ferguson D; Holler T; Hupe D; Nouhan C; Gracheck SJ; VanderRoest S; Saunders J; Iyer K; Sinz M; Brodfuehrer J
Bioorg Med Chem Lett; 1999 Jun; 9(11):1481-6. PubMed ID: 10386921
[TBL] [Abstract][Full Text] [Related]
4. Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding.
Prasad JV; Para KS; Tummino PJ; Ferguson D; McQuade TJ; Lunney EA; Rapundalo ST; Batley BL; Hingorani G; Domagala JM
J Med Chem; 1995 Mar; 38(6):898-905. PubMed ID: 7699705
[TBL] [Abstract][Full Text] [Related]
5. 5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.
Boyer FE; Vara Prasad JV; Domagala JM; Ellsworth EL; Gajda C; Hagen SE; Markoski LJ; Tait BD; Lunney EA; Palovsky A; Ferguson D; Graham N; Holler T; Hupe D; Nouhan C; Tummino PJ; Urumov A; Zeikus E; Zeikus G; Gracheck SJ; Sanders JM; VanderRoest S; Brodfuehrer J; Iyer K; Sinz M; Gulnik SV
J Med Chem; 2000 Mar; 43(5):843-58. PubMed ID: 10715152
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of nonpeptidic HIV protease inhibitors from a cyclooctylpyranone lead structure.
Romines KR; Watenpaugh KD; Howe WJ; Tomich PK; Lovasz KD; Morris JK; Janakiraman MN; Lynn JC; Horng MM; Chong KT
J Med Chem; 1995 Oct; 38(22):4463-73. PubMed ID: 7473573
[TBL] [Abstract][Full Text] [Related]
7. 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
Hagen SE; Domagala J; Gajda C; Lovdahl M; Tait BD; Wise E; Holler T; Hupe D; Nouhan C; Urumov A; Zeikus G; Zeikus E; Lunney EA; Pavlovsky A; Gracheck SJ; Saunders J; VanderRoest S; Brodfuehrer J
J Med Chem; 2001 Jul; 44(14):2319-32. PubMed ID: 11428926
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.
Thaisrivongs S; Romero DL; Tommasi RA; Janakiraman MN; Strohbach JW; Turner SR; Biles C; Morge RR; Johnson PD; Aristoff PA; Tomich PK; Lynn JC; Horng MM; Chong KT; Hinshaw RR; Howe WJ; Finzel BC; Watenpaugh KD
J Med Chem; 1996 Nov; 39(23):4630-42. PubMed ID: 8917652
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of novel 4-hydroxypyrone derivatives as HIV-1 protease inhibitors.
Sun CL; Pang RF; Zhang H; Yang M
Bioorg Med Chem Lett; 2005 Jul; 15(13):3257-62. PubMed ID: 15923115
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of 5,6-dihydro-4-hydroxy-2-pyrones as HIV-1 protease inhibitors: the profound effect of polarity on antiviral activity.
Hagen SE; Prasad JV; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hamilton HW; Markoski LJ; Steinbaugh BA; Tait BD; Lunney EA; Tummino PJ; Ferguson D; Hupe D; Nouhan C; Gracheck SJ; Saunders JM; VanderRoest S
J Med Chem; 1997 Nov; 40(23):3707-11. PubMed ID: 9371233
[No Abstract] [Full Text] [Related]
11. Non-peptidic HIV protease inhibitors: C2-symmetry-based design of bis-sulfonamide dihydropyrones.
Janakiraman MN; Watenpaugh KD; Tomich PK; Chong KT; Turner SR; Tommasi RA; Thaisrivongs S; Strohbach JW
Bioorg Med Chem Lett; 1998 May; 8(10):1237-42. PubMed ID: 9871742
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
Skulnick HI; Johnson PD; Aristoff PA; Morris JK; Lovasz KD; Howe WJ; Watenpaugh KD; Janakiraman MN; Anderson DJ; Reischer RJ; Schwartz TM; Banitt LS; Tomich PK; Lynn JC; Horng MM; Chong KT; Hinshaw RR; Dolak LA; Seest EP; Schwende FJ; Rush BD; Howard GM; Toth LN; Wilkinson KR; Romines KR
J Med Chem; 1997 Mar; 40(7):1149-64. PubMed ID: 9089336
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.
Thaisrivongs S; Janakiraman MN; Chong KT; Tomich PK; Dolak LA; Turner SR; Strohbach JW; Lynn JC; Horng MM; Hinshaw RR; Watenpaugh KD
J Med Chem; 1996 Jun; 39(12):2400-10. PubMed ID: 8691434
[TBL] [Abstract][Full Text] [Related]
14. Cyclic sulfamide HIV-1 protease inhibitors, with sidechains spanning from P2/P2' to P1/P1'.
Ax A; Schaal W; Vrang L; Samuelsson B; Hallberg A; Karlén A
Bioorg Med Chem; 2005 Feb; 13(3):755-64. PubMed ID: 15653343
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
Skulnick HI; Johnson PD; Howe WJ; Tomich PK; Chong KT; Watenpaugh KD; Janakiraman MN; Dolak LA; McGrath JP; Lynn JC
J Med Chem; 1995 Dec; 38(26):4968-71. PubMed ID: 8544171
[No Abstract] [Full Text] [Related]
16. 4-hydroxy-5,6-dihydro-2H-pyran-2-ones.3. Bicyclic and hetero-aromatic ring systems as 3-position scaffolds to bind to S1' and S2' of the HIV-1 protease enzyme.
Ellsworth EL; Domagala J; Prasad JV; Hagen S; Ferguson D; Holler T; Hupe D; Graham N; Nouhan C; Tummino PJ; Zeikus G; Lunney EA
Bioorg Med Chem Lett; 1999 Jul; 9(14):2019-24. PubMed ID: 10450973
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors.
Thaisrivongs S; Watenpaugh KD; Howe WJ; Tomich PK; Dolak LA; Chong KT; Tomich CC; Tomasselli AG; Turner SR; Strohbach JW
J Med Chem; 1995 Sep; 38(18):3624-37. PubMed ID: 7658450
[TBL] [Abstract][Full Text] [Related]
18. Cycloalkylpyranones and cycloalkyldihydropyrones as HIV protease inhibitors: exploring the impact of ring size on structure-activity relationships.
Romines KR; Morris JK; Howe WJ; Tomich PK; Horng MM; Chong KT; Hinshaw RR; Anderson DJ; Strohbach JW; Turner SR; Mizsak SA
J Med Chem; 1996 Sep; 39(20):4125-30. PubMed ID: 8831779
[TBL] [Abstract][Full Text] [Related]
19. Nonpeptidic HIV protease inhibitors: 4-hydroxy-pyran-2-one inhibitors with functional tethers to P1 phenyl ring to reach S3 pocket of the enzyme.
Vara Prasad J; Tummino PJ; Ferguson D; Saunders J; Vander Roest S; McQuade TJ; Heldsinger A; Reyner EL; Stewart BH; Guttendorf RJ; Para KS; Lunney EA; Gracheck SJ; Domagala JM
Biochem Biophys Res Commun; 1996 Apr; 221(3):815-20. PubMed ID: 8630044
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and HIV protease inhibitory activity of new 4-hydroxy-2-pyrone derivatives.
Lee YS; Kim SN; Lee YS; Lee JY; Lee CK; Kim HS; Park H
Arch Pharm (Weinheim); 2000 Oct; 333(10):319-22. PubMed ID: 11092133
[No Abstract] [Full Text] [Related]
[Next] [New Search]
